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Abstract
Background: Sulforaphane (SFN), an isothiocyanate phytochemical present predominantly in cruciferous
vegetables such as brussels sprout and broccoli, is considered a promising chemo-preventive agent against cancer.
In-vitro exposure to SFN appears to result in the induction of apoptosis and cell-cycle arrest in a variety of tumor
types. However, the molecular mechanisms leading to the inhibition of cell cycle progression by SFN are poorly
understood in epithelial ovarian cancer cells (EOC). The aim of this study is to understand the signaling
mechanisms through which SFN influences the cell growth and proliferation in EOC.
Results: SFN at concentrations of 5 - 20 μM induced a dose-dependent suppression of growth in cell lines MDAH
2774 and SkOV-3 with an IC50 of ~8 μM after a 3 day exposure. Combination treatment with chemotherapeutic
agent, paclitaxel, resulted in additive growth suppression. SFN at ~8 μM decreased growth by 40% and 20% on
day 1 in MDAH 2774 and SkOV-3, respectively. Cells treated with cytotoxic concentrations of SFN have reduced cell
migration and increased apoptotic cell death via an increase in Bak/Bcl-2 ratio and cleavage of procaspase-9 and
poly (ADP-ribose)-polymerase (PARP). Gene expression profile analysis of cell cycle regulated proteins demonstrated
increased levels of tumor suppressor retinoblastoma protein (RB) and decreased levels of E2F-1 transcription factor.
SFN treatment resulted in G1 cell cycle arrest through down modulation of RB phosphorylation and by protecting
the RB-E2F-1 complex.
Conclusions: SFN induces growth arrest and apoptosis in EOC cells. Inhibition of retinoblastoma (RB)
phosphorylation and reduction in levels of free E2F-1 appear to play an important role in EOC growth arrest.
Background
Epithelial ovarian cancer is the leading cause of mortal-
ity from gynecological malignancies, often undetectable
in early stage. The difficulty of detecting the disease in
its early stages and the propensity of ovarian cancer
cells to develop resistance to known chemotherapeutic
treatments dramatically decreases the overall survival
[1,2]. Cytoreductive surgery followed by adjuvant combi-
nation chemotherapy is the standard treatment for
advanced stage disease. However, despite these interven-
tions, long-term survival rates remain low underscoring
the need for new effective drugs or drug combinations
with tolerable side effects [3,4].
Epidemiological observations indicate that cruciferous
vegetables such as broccoli, cabbage, cauliflower and
brussels sprouts have been shown to offer protection
against various cancers [5,6]. Phytochemicals such as
glucosinolates are abundant in these vegetables that are
converted into isothiocyanates such as sulforaphane
(SFN) [6-8].
Recently it has been shown that SFN inhibits the
growth of the epithelial ovarian cancer cell (EOC) line
SkOV-3 by down-regulating AKT activity [9]. Related
compounds such as synthetic isothiocyanate derivative
ethyl 4-isothiocyanatobutanoate (E-4IB) and phenyli-
sothiocyanates have been shown to induce apoptosis in
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activity has also been demonstrated in SkOV-3 after
treatment with indole-3-ethyl isothiocyanate (NB7 M)
resulted in the inhibition of PIK3/AKT pathway [14].
Although upstream mechanism of action at the cell sur-
face has been linked to the inhibition of PIK-3 and AKT
pathways in earlier studies, the various down stream sig-
naling pathways responsible for SFN activity are not
thoroughly understood.
The retinoblastoma protein (RB) is a well-known reg-
ulator of G1-S phase cell cycle transition [15]. Negative
regulation of the cell cycle is due to the ability of active,
under phosphorylated RB to bind the transcription fac-
tor E2F-1 and repress transcription required for S phase
progression [15,16]. Here we show that SFN enhances
the RB-E2F-1 interaction in MDAH-2774 ovarian cancer
cell line linking for the first time the upstream AKT
inhibition to the downstream blocking of cell cycle by
activating RB protein. Further we show the inhibition of
invasive ability of cells and reduced migration. Also we
document the increased activity of caspases-9 and also
cleavage of PARP protein indicating inhibition of cell
proliferation and induction of cellular apoptosis.
Materials and methods
Reagents and antibodies
Sulforaphane (Sigma chemicals, St. Louis, MO) was dis-
solved in DMSO and Stock solutions were freshly pre-
pared and added to the cell cultures to obtain the
indicated final concentrations. The DMSO concentra-
tion was used at 0.01% and the same concentration was
used as a vehicle. DMSO alone (0.01%) was found to
have no significant effect on cellular function. Cell pro-
liferation assays were conducted using Cell Counting
Kit-8 (CCK-8) (Dojindo, Gaithersburg, MD). Cell cycle
analysis was conducted using Cell Cycle Phase Determi-
nation Kit (Cayman Chemical Company, Ann Arbor,
MI). Human fibroblasts were similarly treated as cancer
cells to display differential cytotoxicity at any given
dose. Retinoblastoma and E2F-1 antibodies were pur-
chased from Millipore (Danvers, MA). Cyclins, CDKs,
poly (ADP-ribose) polymerase (PARP) and b actin anti-
bodies were purchased from Santa Cruz Biotechnology,
(Santa Cruz, CA).
Cell lines and culture
Ovarian cancer cell lines, MDAH 2774 and SkOV-3
(American Type Culture Collection, Manassas, VA)
were propagated in McCoy’s 5A medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin
(Thermo Fisher Scientific, Pittsburgh, PA). Cells were
cultured in a humidified atmosphere with 5% CO2 at
37°C. Trypsin (0.25%)/EDTA solution was used to
detach the cells from the culture flask for passing the
cells.
Cell proliferation assays
Standard prototype growth curves and number of viable
cells were determined for each cell line (treated and
control groups) in triplicate experiments according to
the CCK-8 (Dojindo, Gaithersburg, MD) manufactures’
instructions. Growth curves were plotted as a percentage
of the value of DMSO-treated controls minus the value
of untreated cells on day 0. Day 3 values were consid-
ered for the determination of the 50% cell proliferation
inhibition (IC50) for a given treatment. In some cases
parallel manual count was also performed with trypan
blue and counting by exclusion method using a Hemo-
cytometer. The findings confirmed CCK-8 assay results.
Analysis of apoptotic cells
Apoptotic cells were analyzed by using Annexin V FITC
apoptosis detection kit (Calbiochem, Gibbstown, NJ)
according to the manufacturers instructions. The DNA
content of the cells was analyzed by flow cytometer and
sub G1 population was considered to represent apopto-
tic cells. For fluorescent microscopic image analysis of
apoptotic fraction of the cells, treated and control (1 ×
10
6 cells/ml) were mixed with annexin V-biotin and
medium-binding reagent, and incubated in the dark for
15 min at room temperature. Cells were then centri-
fuged and medium was replaced with 1× Binding Buffer
containing FITC-streptavidin. Propidium iodide was
added to discriminate early apoptotic cells from late
apoptotic or necrotic cells. A portion of cell suspension
(50 μl) was placed onto a glass slide, covered with a
cover slip, and viewed immediately using a fluorescence
microscope equipped with FITC (green) and propidium
iodide (red) Filters (Zeiss, AXio CamMRm Observer.
A1).
Cell cycle phase determination
MDAH-2774 cells were seeded at 10
6 cells in 10 cm
dishes and the culture medium changed to serum-free
medium for 24 h to facilitate cell cycle synchronization.
Cell cycle analysis was conducted using Cell cycle phase
determination kit according to the manufacturer’s
instructions (Cayman chemical company, Ann Arbor,
MI). Samples were analyzed in FL2 channel of flow cyt-
ometer with a 488 nm excitation laser.
Western blotting and Immunoprecipitations
These assays were performed according to our earlier
publication[17]. Antibody reactions were visualized
using enhanced chemiluminescence western blotting
detection reagents (Amersham Pharmacia, Uppsala,
Sweden).
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Briefly, PANC-1 cells untreated or treated with 15 μM
ritonavir for 48 h, were harvested and total RNA was
isolated utilizing an RNeasy kit (Qiagen Inc., Valencia,
CA) as described by the manufacturer. Total RNA was
sent to MOgene company (MOgene, LC, Saint Louis,
MO) for GEP analysis.
Results
SFN induces growth arrest in ovarian cancer cell lines
To determine if SFN had potential to induce growth
arrest in ovarian cancer cells, we conducted cell prolif-
eration assays using two human ovarian cancer cell
lines, MDAH-2774 and SkOV-3. Cells were grown as
sub-confluent monolayer cultures and propagated under
standard conditions. Cell lines were treated with serial
dilutions of SFN dissolved in DMSO. Human fibroblasts
were similarly treated to display differential cytotoxicity
(data not shown). SFN treatment resulted in a concen-
tration-dependent inhibition of the proliferation of
MDAH 2774 (Fig 1A) and SkOV-3 (Fig 1B) with an
IC50 of ~8 μM. The extent of growth inhibition
increased as a function of time in all the tested doses
ranging from 5 to 20 μM. The extent of cell death with
SFN increased as a function of dosage in 48 h as
observed by phase contract microscopy in MDAH-2774
cell line (Fig. 1C). Since chemotherapy of ovarian cancer
usually consists of paclitaxel alone or in combination
with platinum based drugs, we further evaluated the
influence of SFN combined with paclitaxel in treating
MDAH-2774 cell line. Cells treated with paclitaxel with
or without SFN and viability was assessed for 3 days. As
shown in fig. 1D, 8 μM SFN which is IC50 for MDAH-
2774 or 2 μM paclitaxel alone produced ~40% and
~55% cell death, respectively; however combination
treatment resulted in ~70% cell death.
SFN induces apoptosis MDAH-2774 cells
Inhibition of cell cycle progression in tumor cells may be
associated with a concomitant activation of cell death
Figure 1 Effect of sulforaphane (SFN) on the growth of ovarian cancer cell lines with and without paclitaxel. Cells were cultured for
indicated time intervals with various concentrations of the SFN. Cell growth was assessed by CCK-8 cell proliferation assay method. A and B are
MDAH-2774 and SkOV-3 cell lines respectively. Graph is expressed as a percentage of control (DMSO treated cells) and represents the mean of
triplicate cultures. C. Phase contrast pictures taken at 100× magnification after indicated concentrations of drug treatment of MDAH-2774 cells. D.
Paclitaxel mediated cytotoxicity with or without SFN on MDAH-2774 cells. SFN: Sulforaphane; PTL: Paclitaxel.
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contribution of apoptosis in SFN-treated MDAH-2774
cells. Apoptosis induces changes on the cell surface,
which results in translocation of phosphatidylserine (PS)
from the inner layer of the plasma membrane to the
outer layer [18,19]. Annexin V is a Ca
2+ -dependent pro-
tein with high affinity for PS [19] that was used to assess
apoptotic cells. Flow-cytometric analysis was performed
to quantify apoptotic changes after treatment with SFN.
Control and treated cells were prepared for bivariate ana-
lysis using annexin V stain that detects cells undergoing
apoptosis and propidium iodide (PI) to detect nonviable
cells. The number of pro-apoptotic cells after 48 h of 10
μM SFN treatment was substantially higher as compared
with control. We observed that the ratio of apoptotic
cells increased with the increased dose of SFN treatment:
approximately 8% (5 μM treatment) and 20% (10 μM
treatment) (Fig. 2A) of the cells over 48-hour period.
Further we analyzed cells by immunofluorescence stain-
ing with Annexin V for apoptosis after SFN treatment.
After 48 hr exposure to 10 μM SFN, 60% of the cells
stained positive for annexin V, whereas untreated were
less than 5% annexin V positive (Fig. 2B). As shown in
Fig. 2C, western blotting analysis revealed the activation
of PARP and of caspases-9 from counterpart pro-caspase.
Further we document a dose-dependent increase in pro-
apoptotic BAK and decrease in the expression of the
anti-apoptotic protein Bcl-2.
Figure 2 Analysis apoptotic cells with SFN treatment. A. Apoptotic cells were analyzed by using Annexin V FITC apoptosis detection kit
(Calbiochem, Gibbstown, NJ). Control and SFN treated MDAH-2774 cells (1 × 10
5 cells) were fixed, stained both with Annexin V FITC and with
propidium iodide (20 μg/ml) and were processed for flow cytometric analysis. B. Cells were mixed with annexin V-biotin, incubated for 15 min at
room temperature, and treated with streptavidin conjugated to FITC. Apoptotic cells within the same microscopic field were viewed and
photographed by phase contrast and by fluorescence. Using the FITC filter, early apoptotic cells (positive for Annexin V-Biotin-FITC staining)
appear bright green. C. Western blot analysis of poly (ADP-ribose) polymerase (PARP) protein, caspase 9, BAK, Bcl-2 and control b actin with
increased doses of SFN. Native and cleaved PARP, pro and active caspases are indicated by arrows.
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In order to determine the causes of the growth inhibi-
tion observed by cell proliferation assays, we assessed
the cell cycle progression of the cells in the presence of
SFN. Serum starved MDAH-2774 cells were treated
with either vehicle or 10 μMS F Nf o r1 2o r2 4h r sw i t h
complete growth medium. The cells were then washed,
fixed, and cell cycle phase determination was performed
utilizing flow cytometry and a cell cycle phase determi-
nation kit. The results demonstrated that SFN induces
G1 arrest in a time-dependent manner (Fig. 3D, E and
3F) in comparison with control cells (Fig. 3A, B and
3C). There is a negligible increase of S phase cells after
12 hrs (0.7%) and 24 hrs (2.7%) with SFN treatment
compared with 40% of cells in S phase for control cells
at 24 hrs. Further we observed an overall increase in the
cells at G1 phase of the cell cycle with SFN treatment.
SFN induced modulation of cell cycle regulatory genes
Since we observed cell cycle inhibition with SFN treat-
ment at G0/G1 phase of the cells, we evaluated genes
that influence the cell cycle progression into S phase.
Under phosphorylated tumor suppressor retinoblastoma
proteins (RB, p107 and p130) sequesters cell cycle
promoting E2F-1 transcription factors. Gene expression
analysis of RB proteins revealed a 1.5 and 2.0 fold
decrease of RB and p130, respectively; as well as, a 2
folds increase in p107 levels (Fig. 4A). The E2F family of
proteins, E2F-1, 2 and 3 which interact with RB, demon-
strated 1.0 and 1.5 fold reduction in the expression
levels of E2F-1 and 2, respectively, and 1.0 fold increase
in the levels of E2F-3 (Fig. 4B). Cyclins and cyclin
dependent kinases (CDKs) and their inhibitors exhibit
distinct expression patterns, which contribute to the
temporal coordination of each event in cell cycle pro-
gression. SFN treatment resulted in the decreased
expression of G1 phase cyclins and CDKs while increas-
ing the expression of cyclin dependent kinase inhibitors
(CKIs), which bind and inhibit the activity of cyclin/Cdk
complexes and negatively regulate cell cycle progression
(Fig. 4C, 4D &4E).
Inhibition of the phosphorylation of Retinoblastoma
protein (RB) and protection of RB-E2F-1 complex by SFN
Under-phosphorylated active retinoblastoma protein
(RB) family of proteins, RB, p107 and p130 tumor sup-
pressor proteins control cell cycle progression through
t h el a t eG 1p h a s et ot h eSp h a s eb yi n h i b i t i n gE 2 F
Figure 3 Effect of SFN on DNA synthesis of MDAH-2774 cells. A. Cells were seeded at 10
6 cells and grown serum-free medium for 24 hr for
cell cycle synchronization. Cells were then treated with either vehicle DMSO (i, ii and iii) or 10 μM SFN (iv, v and vi) for 0 hours (i and iv), 24
hours (ii and v) and 48 hours (iii and vi), respectively. Cells were fixed, stained and flow cytometric analysis was conducted using a cell cycle
phase determination kit (Cayman chemical company, Ann Arbor, MI). B. Tabular representation of the % changes in the cell cycle phases. *
Metaphase not reported.
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progressive conversion of phosphorylated RB to non-
phosphorylated RB after 48 hrs with when MDAH-2774
cells were treated with 5 to 15 μM SFN treatment (Fig.
5B upper panel). Further E2F-1 is known to be elevated
in many tumor cell lines and responsible for the expres-
sion of S phase genes that drives cell cycle progression.
We observed decrease in the E2F-1 protein levels with
SFN treatment corroborating cell cycle analysis results
of decreased number of cells in S phase (Fig. 5A).
Cyclins and cyclin-dependent kinases (CDKs) regulate
the activity of RB by phosphorylation resulting in con-
trol of progression through G1 [16]. Since we observed
elevated levels of under-phosphorylated RB, as expected,
we observed lower levels of CDK4 and CDK6, the pro-
teins responsible phosphorylation of RB in response to
SFN in dose dependent manner (Fig. 5A). To assess if
SFN treatment increases the RB-E2F-1 interaction
resulting low levels of E2F-1, we conducted immunopre-
cipitation of cell extracts with E2F-1 polyclonal
antibodies and probed with RB monoclonal antibodies.
We observed a dose dependent increase in the RB levels
in E2F-1 immunoprecipitates (Fig. 5B).
SFN inhibits cell motility and invasiveness
Cell motility following wound generation showed a
greater cell migration in control cells compared with
SFN treated cells. After 20 hrs, we observed almost
complete closure of the wound in control cells which
was inhibited by 50% and 75% by 5 μMa n d1 0μM
SFN, respectively (Fig 6A). Cell migration was also
inhibited when treated with SFN in a modified Boyden
chamber. A progressive decrease in the cell migration
through membrane with the SFN treatment from up to
15 μM was observed (Fig. 6B).
Discussion
SFN mediating cell growth arrest has been documented
in colon, prostate and several other cancers [6-8].
Chaudhuri et al, recently demonstrated that SFN
Figure 4 Gene array analysis of indicated cell cycle regulatory proteins. MDAH-2774 cells were treated with 10 μMS F Nf o r4 8hw e r e
harvested and total RNA was isolated to generate cRNA and was hybridized to Whole Human Genome (G4112A) arrays (Agilent Technologies,
Santa Clara, CA) according to the manufacturer’s instructions. A. Retinoblastoma family of proteins; B. E2F transcription factors; C. Cyclin
dependent kinase inhibitory proteins (CDKIs); D. Cyclins; E. Cyclin dependent kinases.
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inhibition of the AKT pathway is one of the upstream
molecular events [9]. In this report we investigate down-
stream molecular mechanisms at the level of cell cycle
control in the nucleus.
Combination therapy with paclitaxel is known to
increase overall survival [3], but contributes to the
development of resistance phenotype resulting in even-
tual relapse of the disease [22]. Unlike traditional che-
motherapy drugs, natural therapeutics like SFN may not
contribute to the development of chemo-resistant phe-
notype. Our results indicate a synergistic effect of cell
death when SFN was used in combination with pacli-
taxel (Fig. 1D).
SFN treatment resulted in cleavage of Poly (ADP-
ribose) polymerase-1 (PARP-1) in dose dependent man-
ner indicating the induction of apoptosis that was
further confirmed by annexin V staining. Induction of
apoptosis by SFN in different cellular systems is asso-
ciated with Bax protein expression [23]. Similarly the
present study indicates a dose-dependent inhibition of
anti-apoptotic protein Bcl-2 and concomitant increase
in the expression of the pro-apoptotic protein Bak
protein.
Phosphorylated RB cannot interact with E2F-1, thus
leaving large pool of free E2F-1 transcription factors
driving the G1/S cell cycle transition. E2F-1 has been
shown to have growth promoting activity in EOC and is
Figure 5 Protein expression analysis of cell cycle regulatory proteins RB-E2F-1 interactions: A. Approximately 10 μg of protein extracts of
control and SFN treated MDAH-2774 cells were resolved by SDS-PAGE, transferred to nitrocellulose membrane; and probed with E2F-1, CDK-4
and CDK-6 as indicated. b actin was used as a loading control. B. Western blot analysis of SFN treated MDAH-2774 cells (upper panel). SFN
treated MDAH-2774 cell lysates were immuno-precipitated with E2F-1 polyclonal antibody and probed with RB monoclonal antibody (Lower
panel). P-RB: hyper phosphorylated retinoblastoma protein; RB: Under phosphorylated retinoblastoma protein.
Figure 6 Wound healing and cell migration assays. A. Cell motility in wound healing assay. A uniform scratch was made in 80% confluent
monolayer culture of MDAH-2774 cells and the extent of closure was monitored under phase-contrast microscopy as indicated and
photographed. Representative images of two independent experiments done in duplicate are shown. B. Chemotactic migration of MDAH-2774
cells through membrane in Boyden chamber. Logarithmically growing cells were trypsinized and seeded in Boyden chambers and treated with
various concentrations of SFN as described in methods. Migrated cells through the membrane were stained and counted with microscopy.
Results of three independent experiments were plotted.
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[24]. Similarly, studies with histopathology grade 2 ovar-
ian cancers demonstrated that transcription factors E2F-
1 and E2F-2 play a critical role in promoting tumor
metastasis [25]. In our study, gene expression profiling
has demonstrated down regulation of E2F-1 and 2 but
not 3 [25]. Although we observed down regulation of
RB transcript with SFN treatment in gene profile analy-
sis, over 90% of the translated protein product is in the
active, under phosphorylated form. This supports our
hypothesis that the appearance of under phosphorylated
RB with SFN treatment results in the inhibition of cell
cycle progression by the reduction in free E2F-1. Co-
immunoprecipitation experiments also demonstrated the
increased expression of the RB-E2F-1 complex with SFN
treatment potentially adding to the reduction of E2F-1
levels.
Gene profile analysis showed down regulation of these
CDKs with SFN treatment corroborating the under
phosphorylated status of RB. Although SFN treatment is
known to causes induction of p21 in prostate cancer
[26], in our gene profile analysis, we observed a twofold
decrease in p21. It is possible that in the case of ovarian
cancers, CDK inhibition works through the induction of
p15, p18 and p19 following up regulation with SFN
treatment.
Invasion followed by degradation of basal membrane
is hallmark of tumor metastasis where proliferating
tumor cells infiltrate into other tissues [27]. Wound
healing assays and Boyden chamber assays provide evi-
dence that the cell motility and invasiveness are inhib-
ited by SFN. These findings suggested that SFN has very
good potential for use in the treatment against invasion
and metastasis of EOC.
Conclusions
SFN induces growth arrest and apoptosis in EOC cells
by inhibiting RB phosphorylation and reduction in the
levels of free E2F-1. In summary, we have provided evi-
dence that SFN suppresses growth of EOC cells in vitro
by contributing to the modulation of cell cycle regula-
tory proteins and by increasing the apoptosis. These
effects may be correlated to the observed inhibition of
cell migration. These observations highlight the possibi-
lity that SFN may be a good candidate for combination
therapy of EOC with paclitaxel.
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